evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/geneAliases/7,gene/geneAliases/8,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract
10366,GENE_BACKGROUND,,"HRAS (Harvey Ras) is a membrane-associated GTPase. It plays an important role as an upstream mediator of several pro-proliferative and anti-apoptotic signal transduction pathways, including the mitogen activated protein kinase (MAPK) and PI3 kinase (PI3K) pathways. HRAS, NRAS and KRAS comprise the Ras proto-oncogene family, and all three have a similar structure and function. Transforming, gain-of-function mutations of RAS oncogenes tend to disrupt GTPase activity and promote cell proliferation and angiogenesis (PMID: 12778136). Overexpression of oncogenic HRAS also triggers growth factorâ€“independent cell cycle progression and upregulation of proteins implicated in tumor growth (e.g., matrix metalloproteinases 2 and 9). HRAS mutations are found most commonly in cancers of the thyroid, salivary glands, bladder urinary tract, cervix and prostate (PMID: 21993244, 22589270). Patients with Costello syndrome, a hereditary disorder with germline alterations in HRAS, can develop various malignancies at a young age, including neuroblastoma, rhabdomyosarcoma and transitional cell carcinoma of the bladder (PMID: 22261753, 16170316). RAS mutations (including HRAS) have been found in a significant proportion of RET negative medullary thyroid cancer (PMID: 21325462, 23240926, 22865907, 23264394). And while multikinase inhibitors that include HRAS among its targets are FDA-approved for the treatment of medullary thyroid cancer, the FDA-approval is not based on the HRAS mutant status, therefore not explicitly meeting the OncoKB Level 1 criteria.",,2017-09-14,,3265,HRAS,"HRas proto-oncogene, GTPase",True,ENST00000311189,NM_001130442.1,C-H-RAS,HAMSV,p21ras,C-BAS/HAS,HRAS1,CTLO,H-RASIDX,C-HA-RAS1,RASH1,False,21325462,High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.,The Journal of clinical endocrinology and metabolism,2018-05-01T20:11:00,96,5,E863-8,Moura MM et al,doi: 10.1210/jc.2010-1921,,0001-05-01,,21993244,RAS oncogenes: weaving a tumorigenic web.,Nature reviews. Cancer,2018-10-13T20:11:00,11,11,761-74,Pylayeva-Gupta Y et al,doi: 10.1038/nrc3106,,0001-10-13,,22589270,A comprehensive survey of Ras mutations in cancer.,Cancer research,2018-05-15T20:12:00,72,10,2457-67,Prior IA et al,doi: 10.1158/0008-5472.CAN-11-2612,,0001-05-15,,23264394,Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.,The Journal of clinical endocrinology and metabolism,2018-02-01T20:13:00,98,2,E364-9,Agrawal N et al,doi: 10.1210/jc.2012-2703,,0001-02-01,,22261753,Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.,Genetics in medicine : official journal of the American College of Medical Genetics,2018-03-01T20:12:00,14,3,285-92,Gripp KW et al,doi: 10.1038/gim.0b013e31822dd91f,,0001-03-01,,23240926,Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.,Thyroid : official journal of the American Thyroid Association,2018-01-01T20:13:00,23,True,1950-07-01,Ciampi R et al,doi: 10.1089/thy.2012.0207,,0001-01-01,,16170316,Germline mutations in HRAS proto-oncogene cause Costello syndrome.,Nature genetics,2018-10-01T20:05:00,37,10,1038-40,Aoki Y et al,,,0001-10-01,,22865907,Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.,The Journal of clinical endocrinology and metabolism,2018-10-01T20:12:00,97,10,E2031-5,Boichard A et al,doi: 10.1210/jc.2012-2092,,0001-10-01,,12778136,0031-01-01,Nature reviews. Cancer,2018-06-01T20:03:00,3,6,459-65,Malumbres M et al,doi: 10.1038/nrc1097,,0001-06-01,
10365,GENE_SUMMARY,,"HRAS, a GTPase, is mutated in a diverse range of cancers including thyroid, head and neck and bladder cancers.",,2017-04-29,,3265,HRAS,"HRas proto-oncogene, GTPase",True,ENST00000311189,NM_001130442.1,C-H-RAS,HAMSV,p21ras,C-BAS/HAS,HRAS1,CTLO,H-RASIDX,C-HA-RAS1,RASH1,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
